Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]
Acelity said today that it inked a definitive agreement with Allergan (NYSE:AGN) to sell its LifeCell business for $2.9 billion in cash. The deal will put LifeCell’s regenerative medicine and reconstructive portfolio under Allergan’s roof, joining its medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects will generate approximately $450 million in […]
Tela Bio and Acelity subsidiary LifeCell settled their patent infringement beef last month for terms that were not disclosed. Malvern, Pa.-based Tela Bio said the settlement puts to bed all state and federal court cases between the companies and allows it to keep making its OviTex line of reinforced scaffolds for abdominal surgery. “We are very pleased that we were able […]
September 2, 2014 by Brad Perriello
The newly formed medtech alliance comprised of Kinetic Concepts, LifeCell and Systagenix posted collective figures that put the group in the red for Q4, a recent SEC filing shows.
Kinetic Concepts sister company LifeCell this week announced the acquisition of fat-injection devices from California medtech group TauTona.
LifeCell hopes to use the deal, the details of which were not disclosed, to expand its reconstructive and cosmetic portfolio with the fat grafting technology.
Sales took a minor hit for Kinetic Concepts during its 3rd quarter 2013, reporting as part of the Centaur Guernsey companies which now includes both LifeCell and Systagenix.
Kinetic Concepts Inc. said it’s closed the $485 million buyout of fellow privately owned wound-care company Systagenix, which it plans to unite with its LifeCell regenerative therapies unit.
Just weeks after the $485 million merger of Kinetic Concepts and Systagenix, the duo plans to merge forces with LifeCell Corp., forming a 3-headed hydra of wound care, biologics and regenerative therapies.
The new company will be run by KCI president & CEO Joe Woody, with LifeCell commercial operations chief Phil Croxford as senior vice president and "permanent leader" of LifeCell, according to a joint statement.